Jivi

Bayer HealthCare LLC🇺🇸 United States

FDA Page

Effective Date: Mar 2, 2026
Approval ID: f04e5bd5-d7e2-453b-a407-2616d81a695d
Products: 5 registered
Version: 11

Regulatory Information

Labeling Type

PLASMA DERIVATIVE

Status

Approved

Full Title

These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2018

Quick Stats

Total Products5

Labelers2

Label Sections40

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.